Union européenne - français - EMA (European Medicines Agency)

mylan ireland limited - sitagliptin hydrochloride monohydrate, metformin hydrochloride - diabète sucré, type 2 - les médicaments utilisés dans le diabète - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride mylan is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride mylan is indicated in combination with a sulphonylurea (i. triple thérapie de combinaison) en complément d'un régime alimentaire et l'exercice chez les patients insuffisamment contrôlés sur leur dose maximale tolérée de metformine et une sulphonylurea. sitagliptin/metformin hydrochloride mylan is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparg) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparg agonist. sitagliptin/metformin hydrochloride mylan is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Union européenne - français - EMA (European Medicines Agency)

accord healthcare s.l.u. - metformin hydrochloride, sitagliptin hydrochloride monohydrate - diabète sucré, type 2 - les médicaments utilisés dans le diabète - for adult patients with type 2 diabetes mellitus:it is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. it is indicated in combination with a sulphonylurea (i. triple thérapie de combinaison) en complément d'un régime alimentaire et l'exercice chez les patients insuffisamment contrôlés sur leur dose maximale tolérée de metformine et une sulphonylurea. it is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. it is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Union européenne - français - EMA (European Medicines Agency)

accord healthcare s.l.u. - sitagliptin hydrochloride - diabète sucré, type 2 - les médicaments utilisés dans le diabète - for adult patients with type 2 diabetes mellitus, sitagliptin accord is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (ppary) agonist (i. a thiazolidinedione) when use of a ppary agonist is appropriate and when diet and exercise plus the ppary agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a ppary agonist and metformin when use of a ppary agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin accord is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.

Belgique - français - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz sa-nv - chlorhydrate de sitagliptine monohydraté 56,685 mg - eq. sitagliptine 50 mg; chlorhydrate de metformine 850 mg - comprimé pelliculé - 50 mg - 850 mg - chlorhydrate de sitagliptine monohydraté 56.685 mg; chlorhydrate de metformine 850 mg - metformin and sitagliptin

Belgique - français - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz sa-nv - chlorhydrate de sitagliptine monohydraté 56,685 mg - eq. sitagliptine 50 mg; chlorhydrate de metformine 1000 mg - comprimé pelliculé - 50 mg - 1000 mg - chlorhydrate de sitagliptine monohydraté 56.685 mg; chlorhydrate de metformine 1000 mg - metformin and sitagliptin

Belgique - français - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz gmbh - chlorhydrate de sitagliptine monohydraté 56,7 mg - eq. sitagliptine 50 mg; chlorhydrate de metformine 850 mg - comprimé pelliculé - 50 mg - 850 mg - chlorhydrate de sitagliptine monohydraté 56.7 mg; chlorhydrate de metformine 850 mg - metformin and sitagliptin

Belgique - français - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz gmbh - chlorhydrate de sitagliptine monohydraté 56,7 mg - eq. sitagliptine 50 mg; chlorhydrate de metformine 1000 mg - comprimé pelliculé - 50 mg - 1000 mg - chlorhydrate de sitagliptine monohydraté 56.7 mg; chlorhydrate de metformine 1000 mg - metformin and sitagliptin

Belgique - français - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz sa-nv - chlorhydrate de sitagliptine monohydraté 28,343 mg - eq. sitagliptine 25 mg - comprimé pelliculé - 25 mg - chlorhydrate de sitagliptine monohydraté 28.343 mg - sitagliptin

Belgique - français - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz sa-nv - chlorhydrate de sitagliptine monohydraté 56,685 mg - eq. sitagliptine 50 mg - comprimé pelliculé - 50 mg - chlorhydrate de sitagliptine monohydraté 56.685 mg - sitagliptin

Belgique - français - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz sa-nv - chlorhydrate de sitagliptine monohydraté 113,37 mg - eq. sitagliptine 100 mg - comprimé pelliculé - 100 mg - chlorhydrate de sitagliptine monohydraté 113.37 mg - sitagliptin